Filed: March 3, 2015

UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD
MYLAN PHARMACEUTICALS INC. Petitioner,
V.
YEDA RESEARCH & DEVELOPMENT CO. LTD. Patent Owner.
Case IPR2015-00644 Patent No. 8,399,413



TABLE OF CONTENTS

I.	INTRODUCTION			1			
II.	MANDATORY NOTICES			2			
	A.	Real Parties-In-Interest (37 C.F.R. § 42.8(b)(1))					
	B.	Rela	ated Matters (37 C.F.R. § 42.8(b)(2))	2			
	C.		Identification of Counsel (37 C.F.R. § 42.8(b)(3)) and Service				
		Info	Information (37 C.F.R. § 42.8(b)(4))				
	D.	Service Information (37 C.F.R. § 42.8(b)(4))					
III.	GRO	DUND	OUNDS FOR STANDING AND PROCEDURAL STATEMENT				
IV.			NTIFICATION OF CHALLENGE AND STATEMENT OF THE CISE RELIEF REQUESTED4				
V.	THE	RESHO	OLD REQUIREMENT FOR INTER PARTES REVIEW	5			
VI.	STATEMENT OF REASONS FOR THE RELIEF REQUESTED						
	A.	Sum	nmary of the Argument	5			
	B.	Bacl	kground of the '413 Patent	7			
		1.	The '413 Patent	7			
		2.	The Prosecution of the '413 Patent	10			
	C.	Leve	el of Ordinary Skill in the Art	12			
	D.	Claim Construction					
	E.	Pate	nts and Printed Publications Relied On In This Petition	15			
		1.	Pinchasi (Ex. 1005)	15			
		2.	1996 FDA SBOA (Ex. 1007A)				
		3.	Flechter 2002A (Ex. 1008)	18			
		4.	Prior Art Informing the General Knowledge of the Ordinarily-Skilled Artisan				
	F.	Ground 1: Claims 1-6 and 8-20 Are Anticipated by Pinchasi					
		1.	Independent Claim 1 Is Anticipated by Pinchasi	20			
		2.	Independent Claim 19 Is Anticipated by Pinchasi	24			
		3.	Independent Claim 20 Is Anticipated by Pinchasi	25			
		4.	Dependent Claims 2-6 and 8-15 Are Anticipated by				
			Pinchasi.	26			



		a.	Pinchasi expressly disclosed the further limitations of claims 2-3 and 8.	26	
		b.	Pinchasi expressly discloses the further limitations of claims 5 and 12-13.	28	
		c.	Pinchasi expressly disclosed the further limitations of claim 6.	28	
		d.	Pinchasi expressly discloses the further limitations of claim 14-15.	29	
		e.	Pinchasi discloses every limitation of dependent claims 16-18	30	
		f.	Pinchasi discloses every limitation of dependent claims 4 and 9-11	32	
G.	Sumr	nary o	f Petitioner's Obviousness Positions	34	
	1.	The I	Law of Obviousness	34	
	2.	The F	Prior Art Renders the Claims Obvious	37	
		a.	Investigation into Different Dosing Protocols for GA Therapy	37	
		b.	The Prior Art Motivated a Person of Ordinary Skill to Investigate Different Dosing Protocols and Provided A Reasonable Expectation of Success	40	
H.			Claims 1-20 Are Unpatentable As Obvious over	45	
	1.	_	pendent Claims 1, 19 and 20 Are Obvious over	45	
		a.	Dependent claim 7 is Obvious in View of Pinchasi	49	
	2.	-	ndent Claims 2-6 and 8-18 Are Obvious in View of lasi.	50	
I.	Ground 3: Claims 1-20 Are Unpatentable As Obvious over Pinchasi and the 1996 SBOA.				
	1.		pendent Claims 1, 19 and 20 Are Obvious over lasi in view of the 1996 FDA SBOA	51	
	2.	-	ndent Claims 2-18 Are Obvious over Pinchasi and	51	



J.	Ground 4: Claims 1-20 Are Unpatentable As Obvious over Pinchasi and Flechter 2002A			
	1.	Independent Claims 1, 15, and 19 Are Obvious in View of Pinchasi and Flechter 2002A.	55	
	2.	Dependent Claims 2-18 Are Obvious over Pinchasi and Flechter 2002A	56	
K.	•	Secondary Considerations Fail to Overcome the Showing oviousness.	56	
	1.	The Methods Recited in the '413 Patent Produced No Relevant Unexpected Results.	56	
	2.	The '413 Patent Satisfied No Long-Felt But Unmet Need	57	
	3.	Copying By Generic Drug Makers Is Irrelevant	58	

TABLE OF AUTHORITIES

$\underline{\mathbf{Page}(\mathbf{s})}$
CASES
Baldwin Graphic Sys., Inc. v. Siebert, Inc., 512 F.3d 1338 (Fed. Cir. 2008)
Bayer Healthcare Pharms., Inc. v. Watson Pharms., Inc., 713 F.3d 1369 (Fed. Cir. 2013)58
Bristol-Myers Squibb Co. v. Teva Pharms. USA, Inc., 752 F.3d 967 (Fed. Cir. 2014)57
Galderma Labs. v. Tolmar, Inc., 737 F.3d 731 (Fed. Cir. 2013)58
Gillette Co. v. Energizer Holdings Inc., 405 F.3d 1367 (Fed. Cir. 2005)
Graham v. John Deere Co. of Kan. City, 383 U.S. 1 (1966)
Hoffmann-La Roche Inc. v. Apotex Inc., 748 F.3d 1326 (Fed. Cir. 2014)
In re Baxter Travenol Labs., 952 F.2d 388 (Fed. Cir. 1991)
In re Cronyn, 890 F.2d 1158 (Fed. Cir. 1989)18
In re Cuozzo Speed Techs., LLC, No. 2014-31, Slip opinion (Fed. Cir. Feb. 4, 2015)
<i>In re Kubin</i> , 561 F.3d 1351 (Fed. Cir. 2009)
In re Lister, 583 F.3d 1307 (Fed. Cir. 2009)17
In re PepperBall Techs., Inc., 469 F. App'x 878 (Fed. Cir. 2012)58



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

